Free Trial
NASDAQ:LXEO

Lexeo Therapeutics Q1 2025 Earnings Report

Lexeo Therapeutics logo
$3.24 +0.54 (+20.00%)
Closing price 05/16/2025 04:00 PM Eastern
Extended Trading
$2.99 -0.25 (-7.72%)
As of 05/16/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lexeo Therapeutics EPS Results

Actual EPS
-$0.99
Consensus EPS
-$0.80
Beat/Miss
Missed by -$0.19
One Year Ago EPS
N/A

Lexeo Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lexeo Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
7:00AM ET

Lexeo Therapeutics Earnings Headlines

Washington Is Broke—and Eyeing Your Savings Next
Washington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.
Leerink Partnrs Has Bearish Forecast for LXEO Q2 Earnings
See More Lexeo Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lexeo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexeo Therapeutics and other key companies, straight to your email.

About Lexeo Therapeutics

Lexeo Therapeutics (NASDAQ:LXEO) operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

View Lexeo Therapeutics Profile

More Earnings Resources from MarketBeat